Stelara SQ Injection Therapy

See why thousands choose our centers as their preferred destination for ongoing care, including Stelara SQ Injection treatments.

Important Announcement

IVX Health was recently notified by the pharmaceutical manufacturer Janssen that six Medicare Administrative Contractors (MACs) – Palmetto, Noridian, NGS, WPS, Novitas, and First Coast Service Options - are adding the subcutaneous (injectable) formulation of its biologic therapy STELARA to their Self-Administered Drug (SAD) Exclusion List. Effective dates for the policy changes are as follows:

  • October 15, 2021: Palmetto, Noridian, and NGS
  • November 15, 2021: WPS
  • June 6, 2022: Novitas and First Coast Service Options

Medicare will no longer cover STELARA SQ injections under the medical benefit (Part B) and instead will cover STELARA SQ under the prescription benefit (Part D). This change limits the ability of providers, including IVX, to administer STELARA for Medicare patients and generally requires patients remaining on STELARA SQ to self-administer the injection at home.

Due to this classification change, IVX Health is no longer accepting new STELARA SQ patients with Medicare in the following states:

  • Arkansas
  • California
  • Florida
  • Illinois
  • Indiana
  • Kansas / Missouri
  • Pennsylvania
  • Tennessee
  • Railroad Medicare patients in all states

NOTE: IVX Health will continue to accept STELARA IV patients with Medicare.

This change has immediate ramifications to patient care at IVX Health. IVX Health is proactively notifying referring providers about the classification change and the appropriate next steps for their patients. If you are an existing STELARA SQ patient at IVX Health and live in one of the aforementioned states, please contact your local IVX Health center immediately to discuss next steps.

Stelara SQ is a biologic therapy that is indicated to treat:

  • moderately to severely active Crohn’s disease (CD) where treatment with immunomodulators, corticosteroids, or one or more TNF blockers failed
  • active psoriatic arthritis
  • moderate to severe plaque psoriasis with a candidacy for phototherapy or systemic therapy

Stelara SQ targets proteins, IL-12 and IL-23, which are thought to be associated with plaque psoriasis, gastrointestinal, joint and skin inflammation. For Crohn’s patients, Stelara is administered via a single infusion, typically at least one hour, and followed by an injection once every eight weeks until patients have received six total injections. For patients with psoriatic arthritis or plaque psoriasis, Stelara is administered subcutaneously at week one and week 4, followed by doses received every 12 weeks.

Patients chose IVX Health to receive their ongoing Stelara SQ treatments because:

  • ALL private suites
  • Comfortable recliners, with chairs for guests
  • Evening & weekend appointments
  • Friendly clinical staff deliver personal service
  • Big screen TVs, high-speed WiFi, free snacks

Interested in moving your care to IVX Health?

Stelara SQ Financial Assistance Programs

Information about financial assistance programs coming soon.

Stelara SQ Related Blog Posts

The infusion experience is a tough one. So to create this serene, peaceful environment means more than you will ever know.

Jennifer, Patient at IVX Health


IVX Health would love to learn more about your care needs. If you’re interested in switching your infusion services – or if you just want to learn more – let us know.